Abstract Hormone therapy (HT) is prescribed during or after menopausal transition to replace the decline in estrogen and progesterone levels. While some studies indicate that estrogen and progesterone depletion in postmenopausal women might carry a significant risk for developing sporadic Alzheimer's disease (sAD), which may be reduced by HT, recent clinical trials oppose this beneficial effect. This review points to possible reasons for these mixed data by considering the issues of both preclinical and clinical trials, in particular, the representativeness of animal models, timing of HT initiation, type of HT (different types of estrogen compounds, estrogen monotherapy vs. estrogen-progesterone combined therapy), mode of drug delivery (subcutaneous, transdermal, oral, or intramuscular), and hormone dosage used, as well as the heterogeneity of the postmenopausal population in clinical trials (particularly considering their sAD stage, anti-AD therapy, and hysterectomy status). Careful planning of future preclinical and clinical HT interventional studies might help to elucidate the effect of HT on cognitive status in postmenopausal women with sAD, which will eventually contribute to more effective sAD prevention and treatment.
Introduction
Hormone therapy (HT) is prescribed during or after menopausal transition to replace the decline in estrogen and progesterone levels to help women deal with menopausal symptoms. The post-menopausal period represents a distinctly different state of sex hormone homeostasis in which the main circulating estrogen is estrone. Estrone is less potent than 17b-estradiol (referred to as ''estradiol'' in this article) and because of insufficient estrogen activity such a condition consequently leads to the manifestation of menopausal symptoms such as flushing, mood disorders, and osteoporosis [1] , and is accompanied by a decrement in progesterone levels [2] [3] [4] [5] . This hormonal change has shown potential to additionally modulate neural processes and pathology linked to sporadic Alzheimer's disease (sAD) [2] [3] [4] [5] . Some studies have shown that estrogen and progesterone depletion in postmenopausal women is a significant risk factor for the development of sAD and that estrogen-based HT may reduce this risk [3, [6] [7] [8] [9] [10] ; however, more recent data argue against this beneficial effect [11] [12] [13] .
Considering the data from basic research and epidemiological trials, one could hypothesize that HT has a beneficial effect on cognition [3, [6] [7] [8] [9] [10] 14] but a large, longterm, double-blind randomized clinical trial known as the Women's Health Initiative Memory Study (WHIMS) showed that in cognitively unimpaired women, HT can increase the risk of cognitive decline [11, 12, 15, 16] . Recently, a new clinical trial has emerged, the Kronos Early Estrogen Prevention Study (KEEPS), whose substudy the Cognitive and Affective Study (KEEPS-Cog) reported that there is no beneficial effect of HT on cognition [13] . The reasons for such inconsistency in results are not clear and the question of whether HT has a beneficial or detrimental effect on cognition is still open.
Bearing in mind the importance of both preclinical and clinical trials in testing the therapeutic strategy for any disease, this review aims to analyze why there is such inconsistency between the data from preclinical and clinical studies on cognitive outcomes of HT in sAD women. This review discusses the issues of representativeness of animal models, as well as adequate timing of HT initiation, type of drug treatment (type of estrogen compound, treatment with estrogen alone or in combination with progesterone), mode of drug delivery (subcutaneous, transdermal, oral, or intramuscular), and hormone dosage used both in animals and humans.
Search Methodology
Data from preclinical and clinical trials were collected by searching the PubMed/MEDLINE database from 1997 to August 2016 using the terms: 'estrogen', 'Alzheimer's disease', and 'cognition'. Data on basic research covering the mechanism of estrogen and progesterone action were collected from both original scientific papers and reviews by using the terms: 'estrogen', 'progesterone', 'receptor', 'mechanism of action', and 'brain'. Only articles published in English were considered.
Clinical data had to fulfill the following criteria: (1) double-blind, randomized controlled clinical trials investigating the effect of C2 months of HT on cognitive function in postmenopausal women with Alzheimer's disease (AD) [n = 9 studies]; (2) randomized controlled trials of C2.5 years investigating the effect of HT on cognition in cognitively unimpaired women (n = 4 studies); and (3) meta-analyses of HT in perimenopausal and postmenopausal women (n = 4 articles). The reviews from the reference lists of the meta-analysis studies were used as an additional source of data.
The preclinical data search included in vivo experiments on middle-aged and older female animals that were modeled to mimic human menopause and AD-like cognitive decline, and cognitively tested after a sex hormone treatment. Only experiments performed in accordance with the Animal Research: Reporting of In Vivo Experiments guidelines were included.
Estrogen and Progesterone Modes of Action
and Their Effects on Cognition
Genomic Effects
Progesterone and estrogens act through the classic genomic mechanism, which includes the activation of respective nuclear receptors highly expressed in brain areas associated with cognition and emotional processing such as the amygdale and the limbic system [17, 18] . There are two major isoforms of estrogen and progesterone nuclear receptors: estrogen receptor-a and estrogen receptor-b (ERa, ERb), and progesterone receptors A and B (PR-A, PR-B) [19, 20] . Estrogen binds with similar affinity to ERa (Kd = 0.04 nM) and ERb (Kd = 0.11 nM), demonstrating similar potency (ED50 for ERa and ERb is 0.017 and 0.068 nM, respectively) [21] . Activated ERa/b can either bind directly to their target DNA sequences in the nucleus or interact with other nuclear proteins to alter gene activation, and this genomic action occurs slowly (hours to days) [19] .
Basic research has showed that administration of ligands specific for ERb, but not for ERa, has enhancing effects on hippocampal learning and memory processes similar to that of estrogen [22] . These effects are attenuated when ERb expression is knocked down in transgenic models [16] . Zhao et al. showed that oral treatment with a phyto-selective estrogen receptor modulator, which shows 83-fold higher binding selectivity towards ERb over ERa, increases gene expression of apolipoprotein E (ApoE) and decreases expression of amyloid precursor protein and glycogen synthase kinase-3beta in comparison to a soya extract diet (having both ERa/b-acting phytoestrogens) [23] . The same experiment demonstrated increased expression of the insulin-degrading enzyme gene in both phyto-selective estrogen receptor modulator-and soya extract-treated groups in comparison with ovariectomized (OVX) controls [23] .
In contrast, ERa-knockdown mice exhibit impaired spatial memory, which has been improved by treatment with estradiol, while ERb-knockdown mice have preserved cognition and estradiol treatment does not affect their memory [24, 25] . Additionally, activation of ERa is connected to amelioration of amyloid beta (Ab)-induced glutamate excitotoxic injury [26] . These data suggest that it is likely that ERb/a contribute to neuroprotection against age-and AD-related changes but possibly through activation of the transcription of different genes.
Estrogen is also found to increase gene expression of nerve growth factor and brain-derived neurotrophic factor, as well as of choline acetyltransferase (ChAT) in cholinergic neurons and to increase N-methyl-D-aspartate-binding sites, all of which are connected to cognition [27] [28] [29] [30] . Experiments performed in cell cultures and in samples of female rat brains have shown that estrogen protects neurons from Ab peptide-induced toxicity by increasing the expression of Ab clearance factors including insulin-degrading enzyme, neprilysin, endothelin-converting enzyme 1 and 2, angiotensin-converting enzyme, and transthyretin [31] . Although progestogens (progesterone and progestin) bind with relatively high affinity to the PR-A and PR-B, they do not bind to the ER, and their affinities differ towards the androgen, glucocorticoid, and mineralocorticoid receptors [32] . Regarding the neuroprotective effect of progestogens, progesterone increases the gene expression of brain-derived neurotrophic factor and anti-apoptotic Bcl-2 protein. However, the most widely used progestin in HT, medroxyprogesterone acetate (MPA), has no basal effect on Bcl-2 gene expression and inhibits the one elicited by estrogen [33] . Additionally, progesterone reduces the expression of proinflammatory genes and lipid peroxidation, which results in the reduction of cell death [34] .
Non-Genomic Effects
In addition to regulation of gene transcription, progesterone and estrogens can also elicit their effects through rapid non-genomic mechanisms, which include the activation of non-classic membrane-bound receptors found mostly in the hippocampus, hypothalamus, cortex, and substantia nigra [35, 36] . This non-genomic effect can be accomplished also through ERa/b via its interaction with metabotropic receptors [19] . The estrogen membrane receptor was defined as a G-protein-coupled estrogen receptor (GPR30 or GPER1) and the progesterone receptor as a unique G-protein-coupled receptor that acts through cyclic adenosine monophosphate (7TMPR) [18, 37] . Downstream of these non-genomic transduction pathways, both sex hormones can activate multiple signaling pathways, including cyclic adenosine monophosphate/protein kinase A, mammalian target of rapamycin, mitogen-activated protein kinase/extracellular signal-regulated kinases, and protein kinase B, which are involved in synaptic plasticity and neuroprotection [38, 39] . As this is a new field of research, a recent finding that estradiol-elicited mammalian target of rapamycin activation in the hippocampus was blocked by a very specific antagonist of GRP-30 and not by the antagonists of classical ERa/b, places a totally different light on this type of receptor in the context of cognition [39] .
In neurons, progesterone is converted to allopregnanolone, a neurosteroid that binds to the discrete site in the hydrophobic domain of the gamma-aminobutyric acid A (GABA-A) receptor, resulting in the potentiation of GABA-induced chloride conductance [40] . Additionally, GABA-induced chloride conductance can also result from activation of the signal transduction pathway, which consequently phosphorylates certain subunits of the GABA-A receptor [40] . As GABA can impair memory by inhibiting the induction phase of long-term potentiation [41] , allopregnanolone could have a negative influence on the learning process [42, 43] . However, GABA has a positive effect on cell survival in models of excitotoxicity [44] .
Another neurotransmitter involved in the process of learning is glutamate. Progesterone has been shown to suppress the excitatory glutamate response (in a dose-dependent manner), protecting the neurons from glutamate excitotoxicity, while estrogen has the opposite effect by facilitating glutamate transmission [45] . Therefore, the interaction between sex hormones and classic neurotransmitters is a complex one in which estrogen and progesterone can have protective as well as toxic effects.
In summary, the literature suggests that estrogen and progesterone may affect cognition at two levels (which cannot be strictly separated); fast ER/PR-independent (learning, acute response to injury) and slow ER/PR-dependent actions (neurogenesis, memory storage) in the brain areas connected to cognition.
Problems Related to Preclinical Hormone
Therapy Testing
Selection of the Representative Model

Modeling of Human Menopause
Before starting preclinical drug testing, it has to be assured that an appropriate animal model will be used, resembling as much as possible the condition intended for treatment. Considering the HT effects on cognition, it would be Additionally, all animal HT preventive studies have been generally conducted in a condition of surgically induced menopause (OVX model) ( Table 1 ). This does not accord with the physiological human menopausal condition because natural depletion of sex hormones in women is more gradual and less abrupt than the OVX animal model, which, therefore, might be representative only for surgically induced menopause in women.
Our literature search revealed only one animal model with gradual sex hormone depletion, a 4-vinylcyclohexene diepoxide rodent model of ovarian follicle depletion (VCD model) [46] . When this model was used to test the effect of conjugated equine estrogen (CEE), the most common HT used in menopausal women, no beneficial effect was found regarding cognition [46] (Table 1) . However, when CEE was tested on an OVX model, it had a protective effect on cognition [47] (Table 1) , emphasizing the importance of the mode of animal menopause induction in HT testing.
The remaining preclinical research has been performed on OVX female individuals treated with 17b-estradiol with results showing the beneficial effect of estrogen on cognition (Table 1) [48] [49] [50] . Meta-analyses of HT effect on cognition revealed the time-limited positive estrogen treatment effect was seen in women who had recently undergone surgical menopause [51] . Therefore, existing preclinical and clinical research agrees that estrogen treatment (17b-estradiol, CEE) has a beneficial effect in surgically induced menopause. However, to get to the bottom of the problem regarding HT and cognition in naturally menopausal women, experimental models that better mimic the gradual depletion of sex hormones should be used (e.g., VCD or non-human primate model) to improve data translation to humans.
Modeling of Alzheimer's Disease
The modeling issue refers not only to the modeling of hormonal depletion but also to the model of sAD used to test the beneficial effects of estrogen/progesterone therapy. There are only a few preclinical studies in which HT (estrogen and progesterone) was tested to treat experimental AD and they were performed on transgenic mouse models of AD [52, 53] (Table 2) .
Transgenic AD mice models are good for testing the effect of HT on the rare familial early-onset AD (fAD) because they express the gene mutations known to cause fAD in humans [54] . However, the most common form of [55] . Therefore, the existing transgenic mice AD models are not appropriate for testing therapies for sAD, including HT. Testing of the beneficial effects of drugs on cognitive impairment developed in non-transgenic models that more accurately represent sAD-like pathology might achieve better animal-to-human translational results. The general principle behind non-transgenic models is to inject a compound into the brain that causes changes that resemble those of sAD in humans. Existing non-transgenic models include: Ab-based models (Ab 1-42, 1-40), cholinergicbased models (scopolamine, ibotenic acid, choline mustard aziridium), and insulin resistant-based models (streptozotocin); all applied into the brain by various protocols [56] .
Among them, streptozotocin intracerebroventricularytreated rats (STZ-icv model) have been recognized as the model that shares major pathological similarities with the human sAD condition, in addition to cognitive decline [57] . Pathological changes found in this model are the consequence of oxidative stress and a brain insulin-resistant state induced by icv administration of STZ [58] , and an insulin-resistant brain state has been proposed as the metabolic core in human sAD [59] [60] [61] . Neurochemical changes in insulin receptor signaling in the brain as well as cognitive decline in the STZ-icv rat model demonstrate a biphasic time pattern, while structural changes and Ab and tau pathology develop and progress slowly in a linear manner [57, 58] . Such a staging scheme suggests that late changes might correspond to the symptomatic sAD phase in humans [57] . Therefore, the STZ-icv rat model might provide a good platform for both preventive and rescue HT in sAD-like conditions.
To date, only one study has tested the effect of estradiol (200 lg/day for 40 days) on learning and memory in the STZ-icv model [62] . The study found that administration of estradiol immediately after the STZ-icv treatment compensated for the decrease in energy metabolism in the brain and cognitive deficit caused by the STZ-icv treatment (Table 2) .
To date, none of the rodent models described in this section have led to the discovery of a novel useful drug for sAD [63, 64] in humans; however, at the current level of knowledge of AD pathophysiology, use of these animal models is unavoidable in preclinical drug development.
Type of Memory that is Tested
In general, the first and most salient symptom to emerge in patients with sAD is difficulty in the acquisition of new information. Episodic or autobiographical memory is predominantly affected, with early loss of memory for everyday events. Language deficits and visuospatial deficits appear as the disease progresses [65, 66] . Cognitive domains that are frequently affected at an early stage of sAD are: episodic memory, executive functions, semantic memory, and word finding [65, 66] . However, short-term memory, assessed by the digit span, tends to be preserved early in sAD [65, 67] .
Estradiol levels were positively associated with benefits in episodic memory, semantic memory, verbal memory, and verbal learning in premenopausal women [68] [69] [70] [71] [72] . In another study, progesterone levels were significantly positively associated with verbal memory and global cognition, and estradiol was significantly positively associated with semantic memory (naming scores) among women in an early postmenopausal group only [73] . A study in which pregnant women (having high progesterone levels) were compared with controls found that both pregnant groups (early and late pregnancy stages) had reduced scores on immediate and delayed verbal memory tasks, but were unimpaired on visual and procedural memory tasks [74] . These findings demonstrate a relationship between progesterone, estradiol, and cognitive performance that is dependent on the type of memory and the hormone level. It seems that the verbal part of memory is affected the most by sex hormones. Furthermore, in randomized trials, as well as in meta-analyses, verbal memory is found to be positively affected by HT (Tables 3, 4 ) [51] .
The prefrontal and temporal cortices in humans are the parts of the brain associated with semantic verbal memory [75] . Verbal fluency (i.e., generation of semantic category lists) was found to be impaired in sAD as a result of two major constraints: deterioration of the semantic memory store, and variable difficulties in the semantic search [75] .
As semantic memory in humans represents the memory of objects and words, it is a crucial point for performance in verbal and object recognition tests [75] . In animal studies, it is not possible to test verbal memory or to conduct verbal recall tests but it is possible to test object recognition. The delayed response test (involving the prefrontal cortex), delayed non-matching to sample test (involving the medial temporal lobe), or the object recognition test (involving the perirhinal cortex) are the correlates of semantic memory testing in animals. Only a few animal studies with rhesus monkeys have used these tests to explore the effect of HT on cognition and found an improvement or no effect in semantic working memory depending on the HT type and administration regime (Table 1) [76, 77] .
Episodic memory is the sum of cognitive processes involved in the acquisition, storage, and recall of events that happened to the subject directly or the memories of events that happened around the subject [48, 78] . In an animal, this can be translated using a what-where-when [48, 78] . In clinical research, older studies used the Mini-Mental State Examination (MMSE), which is in fact only used as a screening test for dementia [79] . More recent clinical studies have used different cognitive tests that are not always comparable; thus, to avoid inconsistency between clinical trials, the US National Institutes of Health (NIH) have supported the development of a comprehensive assessment tool (NIH Toolbox For Assessment Of Neurological And Behavioural Function; http://www. nihtoolbox.org). The NIH Toolbox provides a specific cognition battery (NIH Toolbox Cognitive Function Battery) to test several cognitive domains (executive function, episodic memory, working memory, attention, processing speed, and language) to be used in intervention studies.
The same would be useful to implement for the preclinical test battery in animal models to avoid the syndrome ''lost in translation''. Until then, when evaluating the effect of HT in cognitive tests in animal models it would be useful to concentrate on the tests that represent semantic memory (delayed response test, delayed matching to sample test, or object recognition test) and that may be closest to verbal semantic memory in humans.
Pharmacological Problems Related to Hormone Therapy
Timing of Prevention Therapy
It might be important to keep in mind the ''healthy cell bias theory'' proposed by Brinton and colleagues, according to whom estrogen is beneficial in healthy neurons (used in vitro) but can become deleterious in diseased neurons [80] . This might explain some of the differences observed between adult and aged rats after HT (Table 1 ) [81, 82] . It could also be the basis for the ''critical window theory'', which suggests that if the pause between starting HT and menopause is too long, hormone treatment can have negative effects or no effect on cognition [78, 83] . However, a meta-analysis of clinical trials concluded that there is no connection between the time of starting the HT and its effect on cognition [51] . It could be hypothesized that health rather than absolute age per se could influence the interaction between HT and cognitive functions [84] . Randomized trials in patients with sAD have also showed that if sAD is at a later stage, the beneficial effect of HT is overwhelmed (Table 3) [85, 86] . In addition, total health status is very important for the metabolism of HT in the liver [87] . Animal studies with different hormone doses used in animals of different ages have demonstrated that the concentration of estradiol is doubled in older animals, probably owing to aging-induced decrements in liver metabolism (Table 1 ) [81] . The same is observed in humans; Hembree et al. [87] found that the clearance of estrogen is slower in older compared with younger postmenopausal women. This issue might account for some of the differences in the effect of HT seen in clinical, as well as in preclinical, studies.
Hormone Therapy Dose and Route of Administration
Oral administration is the most common route of HT administration in postmenopausal women [51, 88, 89] . However, animal studies more commonly use subcutaneous pellets and silastic capsules to deliver HT (Tables 1,  2 ) [49, 78, 83, 88, 90] . The subcutaneous route of administration is associated with different drug pharmacokinetics than oral administration and avoids first-pass metabolism of the hormone, which may result in different outcomes of HT [89] . Indeed, the only preclinical study in which estradiol was administered orally to middle-aged OVX mice and where the effects on cognition were assessed, found that animals had improved performance in the object recognition test but had unaffected spatial working memory and impaired reference memory following estradiol treatment [50] ( Table 1) .
There are few randomized double-blind studies that use the transdermal route of administration in postmenopausal women with sAD (Tables 3, 4) [51, 88, 89] . Therefore, it is important to evaluate the effects of HT in an animal model using a route of administration that is similar to the most common route used in the human population being studied.
Additionally, animal models treated with different HT doses showed that the effect on cognition is dose dependent; lower doses had a beneficial effect, which was not the case with higher doses (Table 1) [38, 47, 83] . HT doses used in patients with AD were the same as those used in healthy women experiencing menopausal symptoms and in view of the animal studies, it seems that new clinical trials with different doses of HT are needed for the sAD population (Table 3) .
As mentioned earlier, it seems that the pharmacokinetics of estradiol is changed in older animals as the same dose administered as silastic capsules to younger and older animals yields almost double concentrations of estradiol in the older animals [81] .
Type (Composition) of Hormone Therapy
The types of hormones prescribed to postmenopausal women are different from those that are most commonly studied in animal models. CEE, the estrogen that was used in the Women's Health Initiative (WHI) [11] , is the most commonly prescribed estrogen, but very few animal studies have evaluated the effects of this particular estrogen on cognition (Table 1 ) [88] . Basic research found a beneficial effect of estrogen on cognition and used estradiol with or without progesterone [78, 83] (Table 1) . A recent study found that CEE administration to middle-aged female rats prevented overnight memory loss in the Morris water maze test only in the group with surgically induced menopause but not in the VCD group (as mentioned earlier, this model better resembles the naturally occurring menopause in women) [46] .
Furthermore, animal studies that have evaluated the effects of progestogens on cognition have used progesterone rather than MPA (the most commonly prescribed progestin in humans) (Table 1) [49, 75, 83, 88, 90] . MPA is a synthetic analog of progesterone and acts like an agonist at progesterone receptors, but it also binds to androgen and glucocorticoid receptors, respectively [91, 92] . A recent study found that MPA administered without estrogen impaired the performance of rats in the water radial arm maze and the spatial water maze tests [93] .
The impact of progestin on estrogen-induced neuroprotection depends on the type of progestin; it is synergized by progesterone and 19-norprogesterone and antagonized by MPA [33] . The WHIMS used MPA, which could explain why HT worsened the cognition in postmenopausal women (Table 4) [11, 15, 16] . Formulations that contain a combination of CEE and MPA are commonly prescribed clinically for the relief of hot flashes and related symptoms [16, 51] , but the effect of treatment on cognitive function in postmenopausal women remains controversial [10, 39] .
Therefore, it is important to test different combinations of hormones both in preclinical and clinical trials. One clinical study has found a beneficial effect of 19-norprogesterone [94] , which accords with preclinical findings on cultured neurons [33] . Furthermore, a beneficial effect of norethisterone in combination with estradiol has been found in randomized clinical trials in healthy as well as in sAD postmenopausal women [95, 96] . KEEPS used treatment with two types of estrogen (CEE orally and 17b-estradiol in a transdermal patch with or without micronized progesterone [MP]) and did not find any beneficial effects on cognition [13] (Table 4) . However, in a group of ApoE e4 carriers treated with low concentrations of estradiol (50 lg), lower levels of Ab deposits were found in comparison to non-carriers [97] .
A meta-analysis of randomized trials that assessed the cognitive effect of HT in menopausal women showed that adding progestogens to estrogen therapy negatively affected the outcome [84] . Interestingly, 9 out of 13 clinical trials used MPA as the add-on progestin [84] . There are also studies that have used a synthetic partial agonist of the estrogen receptor, raloxifene; raloxifene administered to animals improves memory [98, 99] , but clinical research has reported mixed findings (beneficial effect in some [100, 101] and no effect in others [102, 103] ).
From these data, one could speculate that different types of estrogen and progesterone independently and interactively regulate AD-like neuropathology, suggesting that tailored and optimized HT may be more successful in reducing the risk of AD in postmenopausal women. Additionally, future efforts should concentrate on finding new selective modulators that have the beneficial effect on cognition and no adverse effects on the periphery, and possibly to combine them with a proper progestogen compound.
Problems Related to Design of Hormone
Therapy Clinical Trials
Randomized Interventional Clinical Trials in Women with Unimpaired Cognition
According to the four meta-analyses published during the past 20 years, the findings of previous observational clinical studies have not been consistent; three meta-analysis estimated that the risk of dementia was reduced by 29-44 % [51, 104] , while the fourth one showed no risk reduction [105] .
Data from large randomized clinical trials have also been mixed. On the one hand, there is WHIMS, and the Women's Health Initiative Memory Study of Cognitive Aging (WHIMSCA) reporting a negative effect of HT on cognition. [11, 15, 16] On the other hand, the Women's Health Initiative Memory Study/Young (WHIMS-Y) and KEEPS-Cog showed no beneficial effect on cognition (Table 4) [13, 106] .
Choosing the Right Population
WHIMS, which was the largest multi-center, randomized, double-blind, placebo-controlled clinical trial designed to assess the effects of HT on the risk of dementia and mild cognitive impairment, found that continuous HT use (CEE with or without MPA/the latter in hysterectomized women) was associated with an overall significant increase in dementia risk (Table 4) [11, 15, 16] . However, despite the valuable findings that came out of this study, there are some limitations that should be considered. First, the women enrolled were aged 65 years or older, which could have been associated with an increased risk of cardiovascular and/or cerebrovascular diseases, thus it could not be excluded that the high risk of dementia was attributed to the concomitant vascular disease ( Table 4) . As reported in the WHI study, women taking HT have an increased risk for cardiovascular disease and those with higher levels of low-density lipoprotein-cholesterol at the beginning of the study were associated with an excess risk of coronary heart disCompliance with Ethical Standards ease among HT users [107] . Second, there was no baseline cognitive testing and thus the results were based only on a cross-sectional analysis performed at the end of the study. Third, all types of dementia were classified in the same category without subdivision into AD, vascular dementia, Parkinson's dementia, and frontotemporal dementia [11, 15, 16] .
To address some of these limitations, the WHIMS-Y was designed as a sub-trial of the WHI study that enrolled only younger postmenopausal women aged 50-55 years but found no effect of HT on cognition (Table 4 ) [106] . However, apart from age and dementia status at enrollment, the other limitations remained the same in the WHIMS-Y [106] .
The WHIMSCA, in contrast, enrolled older women (mean age 74 years) and found that CEE alone had no effect on verbal and figural memory, but in combination with MPA, verbal memory declined and figural memory improved [108, 109] .
In summary, it seems that if one has an increased risk for cardiovascular disease and is taking HT (CEE ± MPA), then one has increased risk for developing all-cause dementia, but any effect remains unknown in healthy women.
Additionally, a recent large randomized double-blind study, KEEPS-Cog, showed no effect of estradiol and MP on cognition but rather a beneficial effect of estradiol on amyloid deposits in ApoE e4 carriers (Table 4) [13, 97] . This study enrolled a large sample of recently postmenopausal women, aged 42-58 years, without a high cardiovascular risk (normal blood pressure, mean body mass index 26.3, normal lipid levels), with a mean MMSE of 29.1 (cut-off \ 23) and naturally occurring menopause. In comparison to WHIMS, the KEEPS-Cog study used a different type and dose of hormones (low-dose CEE, estradiol, and MP vs. high-dose CEE and MPA in WHIMS) and two routes of hormone administration (oral and transdermal) [13] . This study also pointed to the importance of the ApoE e4 carrier status and a need for patient stratification in this regard.
Findings from KEEP-Cog and WHIMS-Y showed that high-or low-dose CEE and progestogens (MPA, MP) have no protective effect on cognition in recently postmenopausal women. There may be a little spark of hope that unopposed estradiol given transdermally could have a postponed protective effect on cognition but only in ApoEe4 carriers [97] . Thus, it is important to consider all risks and benefits that HT could bring, depending on an individual's risk profile. Further research should be designed to clarify the effect of other types of HT (both regarding the hormone compound and the pharmaceutical formulation) on cognition in recently postmenopausal women.
Randomized Interventional Clinical Trials in Women with Alzheimer's Disease
Since 1997, nine randomized double-blind controlled trials of HT women with AD have been conducted, among which six had primarily positive results (improved visual and verbal memory) [96, [110] [111] [112] [113] [114] , while in three there was no effect on memory [86, 115, 116] (Table 3) . [96, 112, 114] ). The two of them with the smallest number of participants (12 and 20) and with the shortest duration (13 and 16 weeks) were conducted by the same investigational team [110, 111] . Both included women with mild to moderate sAD, with natural or surgical menopause, who were treated with an unopposed transdermal formulation of estradiol that was reported to have a beneficial effect on verbal and visual memory [110, 111] . In both studies, ApoE status was not assessed and the duration of sAD from diagnosis until HT was 2.2-5 years. In both of the studies, no effects were found in MMSE and the BlessedMemory-Information-Concentration Test (BMICT) representing global cognitive function [78, 79] . A positive effect was found on verbal and attentional memory (Table 3 ). In the third study conducted by the same team, women were treated with estrogen plus MPA, and no positive effect was found on verbal memory, but positive effects were seen on semantic and episodic visual memory [112] .
Apolipoprotein E Status
As mentioned previously, ApoE e4 status is an important factor that can change the way that HT affects cognition in healthy perimenopausal women. The study by ValenSendstad et al. [96] on women with sAD demonstrated that only women who were ApoE e4 negative showed better performance on a verbal memory task (Table 3 ) [96] . The other randomized studies did not stratify women regarding their ApoE status (Table 3) . Future studies should pay attention to whether or not women are ApoE4 carriers.
Trials with [100 Patients
Among nine studies in AD postmenopausal women, only two had more than 50 patients but their number barely exceeded 100 (120 [86] and 117 [115] ). However, there are certain facts that may be highlighted in these studies as possible influencing factors on cognitive outcomes.
Concomitant Drug Therapy
Rigaud et al. conducted the largest study [115] on 117 patients who were all receiving concomitant therapy with the acetylcholinesterase (AchE) inhibitor rivastigmine. The advantage of this study is that all patients were diagnosed to have sAD for approximately 1.7 years before entering the study but no particularly co-morbidity was reported [115] . The results of this study indicated that transdermal estradiol opposed with progesterone had no effect on cognition [115] . In other studies, the AchE inhibitors were omitted 2-3 months prior to the beginning of the study [96, [110] [111] [112] [113] [114] 116] except in The Alzheimer's Disease Cooperative Study (ADCS) [86] where 24 % of women in the CEE group and 13 % in the placebo group remained on donepezil therapy (Table 3) [86, 96, [110] [111] [112] [113] [114] 116] . Bearing in mind that estradiol enhances cholinergic-mediated cognitive performance [117] [118] [119] and that the combination of estrogen and cholinergic treatment may improve cognitive performance in animals as well as in humans [84] [85] [86] , it is problematic to compare the results of these studies. Additionally, in the ADCS, five patients were taking donepezil in the placebo group compared with ten and nine patients in the estrogen-treated groups (Table 3 ) [86] .
However, it cannot be excluded that possible chronic concomitant drug therapy other than anti-AD therapy could have influenced cognitive outcomes in these studies. This might be important particularly regarding the drugs used to treat diseases of the cardiovascular system and diabetes mellitus whose influence on dementia has been investigated in AD populations (e.g., calcium channel blockers [121, 122] , statins [123, 124] , metformin [125] , insulin [126] and rosiglitazone [122, 125, 127] ). Unfortunately, such concomitant therapy has been explicitly mentioned in inclusion/exclusion criteria in only a few studies [96, 110, 111] (Table 3) , while no data have been provided for the co-morbidity of diabetes mellitus (Table 3) , a disease that itself carries a risk for AD development [128, 129] .
Duration of sAD Before Hormone Therapy
It is also important to consider the issue of duration of the sAD condition prior to HT (Table 3) . Typically, the patients have mild to moderate sAD with similar scores on cognitive tests (MMSE as inclusion criteria), but if one considers the healthy bias theory and the appropriate time to start HT, then it would be useful to know the duration of the disease before starting the therapy and, if possible, which part of the brain has been affected at that stage. This seems to be important considering the preclinical results showing a ChAT protein level is altered in a site-specific manner after treatment with estradiol [120] . This research demonstrated that estradiol treatment initiated immediately after an ovariectomy significantly increased ChAT levels in the middle-aged rat hippocampus but not in the prefrontal cortex while the vice versa effect was induced by estradiol treatment initiated 5 months after an ovariectomy; it increased ChAT levels in the prefrontal cortex, but not in the hippocampus [120] . With this in mind and looking back at the ADCS, there is a higher percentage of patients with mild sAD (74 %) in the placebo group in comparison to similar sAD-staged patients in the estrogen-treated groups (55 %), while other patients in both groups had moderate sAD (26 % in the placebo group and 45 % in the estrogentreated group) [86] . This may indicate that at the beginning of the study the participants in the estrogen group were at a disadvantage regarding the timing of HT in comparison to the placebo group.
Baseline Serum Estradiol Level
The ADCS (120 patients enrolled) found no effect on cognition in surgically induced postmenopausal women, but the mean baseline serum estradiol levels were 5.4 pg/ mL in the placebo group (n = 35), 48.0 pg/mL in the lowdosed estrogen group (n = 42, concomitant treatment with 0.625 mg of CEE per day), and 58.4 pg/mL in the highdosed estrogen group (n = 39, concomitant treatment with 1.25 mg of CEE per day) [86] (Table 3) . It can only be speculated that the reason for such a huge difference in the mean baseline serum estradiol levels between the groups was owing to previous estrogen-based treatment or because of a large inter-group age range (55-91 years).
Pharmacokinetics and Pharmacodynamics of Hormone Therapy
Another methodological inconsistency between the clinical studies can be observed in the pharmacological aspects; the type of HT (estrogen compound), route of hormone administration (pharmaceutical formulation), opposed or unopposed with progestogens, and inter-individual differences in hormone levels achieved following HT (not assessed in any of the studies) (Table 3) . Some trials tested oral CEE, while in others transdermal estradiol was used (Table 3) , which might be a source of biotransformationrelated differences; as women become older, the pharmacokinetics of sex hormones is changed and estradiol is metabolized more rapidly in the early vs. late stage of menopause [87] . Timing of cognitive testing following the HT initiation seems to be very important as well. The largest randomized study conducted by Kantor et al. that lasted for 38 months has reported that the beneficial effect of CEE treatment in sAD patients begins between 6 and 9 months after the HT initiation and lasts for 12 months of therapy, while after that, the test scores decline [65] . This observation suggests that CEE therapy may improve cognition at the beginning but eventually disease progression overwhelms the beneficial effect of HT.
To summarize, the design of the clinical trials, in particular intra-and inter-group heterogeneity in the sAD stage, concomitant AchE inhibitor or other drug therapy, co-morbidity, patient age, and hysterectomy status, seems to have a large impact on the inconsistency of the results of HT clinical trials in postmenopausal women with sAD. This may be further complicated by the different sensitivities of cognitive tests used to measure the primary outcome.
Although this review may have some limitations related to the single database used as a source of information and particular inclusion criteria used in the searches (time frame, article type), preclinical and clinical trials that have been critically evaluated as a result of such searches seem to provide a rather representative sample of a larger number of similar studies dealing with the issue of HT influence on cognition.
Conclusion
While there are studies showing that estrogen and progesterone depletion in postmenopausal women carries a significant risk for developing AD, which may be reduced by estrogen-based HT, data from recent clinical trials oppose this beneficial effect. Possible reasons for such an inconsistency might be found both in preclinical and clinical trials as well as in the HT itself:
1. Inappropriate animal model (incorrect translation of the animal-to-human or human-to-animal condition of sex hormone depletion; abrupt/surgical or gonadal/physiological, widely exploited models represent rare familial AD but not the prevailing sporadic AD).
Heterogeneous postmenopausal women groups in
clinical trials (particularly regarding the sAD stage, anti-AD therapy, hysterectomy status, possible comorbidity, and concomitant drug therapy). 3. Incomparable HT design (different estrogen/progestogen composition as well as dose and route of administration, pharmaceutical formulation, timing of treatment initiation, as well as type of cognitive testing).
Further research is needed both in humans and animals that will be focused on other types of estrogen and progestogen compounds including other progestins besides MPA (e.g., norprogesterone, levonorgestrel, and others) and selective modulators of estrogen receptors. It is essential to have randomized controlled double-blind studies in populations with uniform early stages of AD and patient groups that are more homogeneous regarding AchE inhibitor therapy (or other anti-AD therapy), age, and hysterectomy status as well as co-morbidity condition and ApoE carrier status, to elucidate and define the therapeutic role of different HT for postmenopausal women with AD. As we probe deeper into the mechanisms underlying the effects of estradiol and progesterone and their pharmacokinetics, we will be able to design estrogen/progesterone modulators to optimize the cognitive benefits for the possible prevention and treatment of AD and to minimize the associated side effects.
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